File photo: A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Reuters Novo Nordisk said on Monday it would halt its ...

Novo Nordisk has been actively pursuing licensing deals over the past six months. There are other good reasons to consider investing in Novo Nordisk right now. It wasn't so long ago that Novo ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight ...

Novo Nordisk dished out an up-front payment of $200 million (not to mention potential milestone payments of up to $1.8 billion) to acquire UBT251, a triple agonist -- that is, a medicine that ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy and Ozempic, according to Danish media Finans.

Novo Nordisk’s Wegovy did around $8 billion in sales in 2024, in a market that is expected to grow to be worth $150 billion by 2030.

Victor Golmer In the aftermath of several deals with smaller biotechs made in the 13 months in the cardiometabolic space, Novo Nordisk has no plans to pursue deals with biotechs in other indications.

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say the company's cautious culture is to blame.

As for improving access to obesity treatments, Novo has, in recent months, brought down the out-of-pocket price for Wegovy. In March, it began offering a one-month supply to self-paying customers ...